Loading...
NPI 1700828522 · Aiea, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Aiea, Hawaii. This profile covers 10 Medicare and 13 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 98 1005 Moanalua Rd Spc 400 |
| City | Aiea |
| State | HI |
| ZIP | 96701 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $293K |
| Medicaid | $58K |
LONGS DRUG STORES CALIFORNIA LLC shows a clear retail immunization and testing operational profile: its top Medicare revenue drivers are vaccine and COVID-test related codes such as 91322 (SARS–CoV–2 vaccine), 90694 (influenza vaccine), and K1034 (nonprescription self‑administered COVID test), indicating the location primarily performs point-of-care vaccination services and high-volume COVID test dispensing for Medicare beneficiaries. This code mix is consistent with a community/retail pharmacy taxonomy rather than a clinic or long‑term care provider.
Revenue concentration is high within each payer: the top 3 Medicare codes account for 66.5% of this provider’s total Medicare revenue, specifically 91322 at 28.1%, K1034 at 21.0%, and 90694 at 17.4%. On the Medicaid side the top 3 codes account for 65.1% of Medicaid revenue, led by 0012A at 29.8%, 0011A at 25.3%, and 90471 at 9.9%, showing similar dependence on a small set of services for both payers.
The payer mix is Medicare‑heavy in scale: lifetime Medicare revenue is $293K compared with total Medicaid revenue of $58K, indicating Medicare receipts are the primary source of billed public-payer income for this NPI. While both payers appear in the file, Medicare activity is roughly an order of magnitude larger based on the provided totals.
Competitive standing versus peers is mixed but leans toward above‑median activity on vaccination/testing codes: for Medicare, 91322 ranks #278 of 29357 providers nationally (99th percentile) and 90694 ranks in the 99th percentile as well, while K1034 ranks in the 98th percentile — the dataset labels these as "typical, unremarkable volume" for those codes, but the numeric ranks place the site well above many peers on these vaccine/test services. For Medicaid in‑state comparisons, 0012A and 0011A rank #9 and #8 of 88 providers (91th and 92th percentiles) and are described as typical volumes, indicating this location is among the more active in‑state providers for whatever services those two codes represent.
There are notable code-level distinctions that may affect service strategy: Medicare administration codes such as G0008 (influenza administration) and 90480 (COVID‑19 vaccine administration) both appear with substantial claim counts and are at high national percentiles (G0008 listed at the 100th percentile, 90480 at the 98th), reinforcing that on-site vaccine administration is a consistent service line. Conversely, certain pneumococcal administration codes (e.g., 90732 at the 37th percentile) appear at lower relative standing, suggesting the site’s mix favors influenza/COVID vaccination and test dispensing over some other adult immunizations.
The presence and scale of K1034 (6.1K claims, $61.1K revenue) alongside multiple COVID and flu vaccine codes demonstrates a dual role of dispensing/tests plus administration: the location is processing large volumes of nonprescription self‑administered COVID tests while concurrently delivering on-site immunizations. This combination is characteristic of community pharmacies that integrate retail distribution with clinical vaccine services rather than pharmacies that only fill prescriptions.
A small volume of pharmacy-compounding or dispensing‑labeled activity is present but not revenue‑material in Medicaid: S9430 shows 34 claims with $0 revenue and ranks low in‑state, indicating compounding/dispensing billed under that code is not a meaningful revenue stream for Medicaid from this NPI. Other lower-revenue vaccine codes in Medicaid (e.g., 90674, 90686) have modest rank positions, reinforcing that Medicaid revenue is concentrated in a couple of high-count codes rather than broadly across many vaccine types.
This NPI has long tenure in the registry, having been enumerated on 2006-06-13 (~20 years ago), which supports an interpretation of an established retail site with sustained operations rather than a recently opened location. Given the profile—high Medicare vaccine and test activity, concentrated revenue by a few codes, and above‑median percentile ranks on key services—the site should be considered an established, pharmacy‑focused immunization and COVID testing provider in its market.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 570 | $140 | $81.9K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 6,110 | $10 | $61.1K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 680 | $80 | $50.7K |
| G0008 | Administration of influenza virus vaccine | 820 | $30 | $25.5K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 570 | $40 | $24.7K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 70 | $280 | $20.1K |
| 0134A | N/A | 340 | $40 | $14.5K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 140 | $70 | $9.9K |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 10 | $130 | $1.8K |
| G0009 | Administration of pneumococcal vaccine | 80 | $10 | $1.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0012A | N/A | 470 | $40 | $17.2K |
| 0011A | N/A | 470 | $30 | $14.6K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 520 | $10 | $5.7K |
| 0064A | N/A | 140 | $40 | $5.3K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 40 | $110 | $5K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 110 | $20 | $2.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 140 | $20 | $2.4K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 50 | $40 | $2.1K |
| 0134A | N/A | 30 | $40 | $1.5K |
| 90661 | This code represents a vaccine product administered into the muscle to protect against the flu virus. This is a trivalent vaccine, meaning it protects against three different strains of influenza.… | 30 | $30 | $900 |
Showing 1–10 of 13
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
13 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90472 | This code represents each injection of a vaccine after the first; list this code in addition to the code for the first injection. | 42 | 50 | 50 | $40 | $33.1K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 57 | 230 | 140 | $20 | $16.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 18 | 30 | 50 | $110 | $7.7K |
| 0012A | N/A | 9 | 90 | 70 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 80 | 180 | 120 | $10 | $4.7K |
| 0011A | N/A | 8 | 90 | 80 | $20 | $4.4K |
| 0064A | N/A | 22 | 100 | 60 | $30 | $3.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 28 | 60 | 50 | $30 | $2.8K |
| 0134A | N/A | 20 | 40 | 30 | $30 | $1.5K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 11 | 60 | 50 | $20 | $1.3K |
Showing 1–10 of 13
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.